Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conway Stuart Stretta GERD Clearance Expected By April 2000

This article was originally published in The Gray Sheet

Executive Summary

Conway Stuart's Stretta radiofrequency ablation catheter and control module could gain 510(k) approval for the treatment of gastroesophageal reflux disease (GERD) as early as April 2000, company founder Stuart Edwards reported Oct. 28.

You may also be interested in...



Advanced UroScience Durasphere Post-Approval Study Focuses On Durability

Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.

Bard Anticipating Endoscopic Suturing Device Sales By Second Quarter 2000

Bard expects to add roughly $5 mil. to its top line during the first year of sales of its endoscopic suturing device for treatment of severe gastroesophageal reflux disease (GERD).

Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier

Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel